T. Kerre Archives - Page 4 of 7

From Minis to TRUCKs: are CARs ready for the highway?

BJH - volume 8, issue 3, june 2017

T. Kerre MD, PhD

SUMMARY

CAR T-cells have revolutionised the treatment of relapsed and refractory B-cell malignancies. Especially in B-ALL, exciting results have been published. This article reviews CAR T-cell design, the optimal T-cell product used, the lymphodepleting regimen preceding the adoptive therapy, successes and toxicities induced by CAR T-cells in clinical trials (especially B cell malignancies), and the future of CARs and their position in the quickly evolving field of targeted therapies and immunotherapy for haematological malignancies.

(BELG J HEMATOL 2017;8(3):94–101)

O.5 Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): an interim analysis from the Belgian Hematology Society (BHS)

BJH - volume 8, issue Abstract Book BHS, february 2017

X. Poiré MD, PhD, C. Graux MD, PhD, A. Ory , J. Jamart , F. Frédéric , H. Schoemans MD, PhD, P. Lewalle MD, PhD, A. De Becker MD, D. Deeren , Z. Berneman MD, PhD, T. Kerre MD, PhD, P. Zachée MD, PhD, D. Selleslag MD, Y. Beguin MD, PhD

O.4 In vitro generation of tumor antigen-specific T cells from patient and healthy donor stem cells

BJH - volume 8, issue Abstract Book BHS, february 2017

S. Bonte PhD, S. Snauwaert MD, PhD, G. Goetgeluk , B. Vandekerckhove MD, PhD, T. Kerre MD, PhD

Occurrence of mild spontaneous graft-versus-host disease after autologous stem cell transplantation for multiple myeloma: a case report and review of the literature

BJH - volume 7, issue 2, april 2016

I. Moors MD, L. Noens MD, PhD, T. Kerre MD, PhD

Summary

We present the case of a 68 year old woman with multiple myeloma, who developed mild persistent upper and lower gastrointestinal symptoms, together with a rash and abnormal liver function tests, in the early phase post-autologous stem cell transplantation. Pathology findings were compatible with graft-versus-host disease. Local treatment with corticosteroids resulted in a durable remission of the autologous graft-versus-host disease. A literature review reveals an incidence of mild gastrointestinal graft-versus-host disease in 13% of patients after autologous stem cell transplantation. Severe fatal autologous graft-versus-host disease has rarely been reported, and solely in multiple myeloma patients. In this article we discuss incidence, pathophysiology, outcome and treatment of these entities.

(BELG J HEMATOL 2016;7(2):83–6)